Hong Kong IT Stock News

Investors in China Hongqiao Group Limited ( HKG:1378 ) had a good week, as its shares rose 2.3% to close at HK$23.48...

It's been a good week for Jinxin Fertility Group Limited ( HKG:1951 ) shareholders, because the company has just...

China Petroleum & Chemical Corporation ( HKG:386 ) just released its latest half-yearly report and things are not...

As you might know, Shanghai Henlius Biotech, Inc. ( HKG:2696 ) recently reported its interim numbers. It was a...

Last week saw the newest half-year earnings release from China Resources Building Materials Technology Holdings Limited...

As of August 2026, Asian markets have been navigating a complex landscape marked by global economic uncertainties and fluctuating investor sentiment. Despite these challenges, opportunities for value investing persist, with certain stocks trading at a discount offering potential for growth in the long term. Identifying undervalued stocks involves looking for companies with strong fundamentals that remain resilient amid broader market volatility.

As global markets navigate a complex landscape marked by rising oil prices and geopolitical tensions, investors are increasingly turning their attention to opportunities in Asia. Penny stocks, though often seen as relics of past market eras, continue to capture interest due to their potential for growth and affordability. By focusing on companies with strong financial foundations, investors can uncover promising opportunities within this segment of the market.

Huaneng Power International (SEHK:902) reported half year 2026 results that showed lower revenue and net income compared with the same period in 2025. The earnings update appears to have influenced recent trading in the stock. See our latest analysis for Huaneng Power International. Since the earnings announcement on 18 August 2026, Huaneng Power International’s share price has been volatile, with the stock at HK$5.45 after a 1 day gain of 1.11% but a 90 day share price return that has fallen...

Investors in Xinyi Solar Holdings (SEHK:968) are assessing a fresh leadership shift after the company announced the retirement of executive director and financial controller Mr. Chu Charn Fai and the appointment of Mr. Lam Chi Kwong. See our latest analysis for Xinyi Solar Holdings. At a latest share price of HK$2.345, Xinyi Solar Holdings has seen a 1 month share price return of 11.14%, yet its year to date share price return is down 23.37% and the 5 year total shareholder return is down...

WuXi Biologics (Cayman) half year earnings in focus WuXi Biologics (Cayman) (SEHK:2269) reported half year 2026 earnings, noting higher sales, net income and earnings per share compared with the same period in 2025. See our latest analysis for WuXi Biologics (Cayman). Alongside these half year results, WuXi Biologics (Cayman) has seen strong recent momentum, with a 30 day share price return of 33.5% and a 90 day share price return of 54.99%, while the 1 year total shareholder return is...

HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors. See our latest analysis for HBM Holdings. The HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...

Mobvista entered this earnings season with a growth stock label and a rich 29.5x trailing P/E. However, the share price has slipped 1.7% over the past week and 23.7% over three months. The latest quarter explains some of that unease. Q2 2026 net income came in at US$12.5m on revenue of US$574.3m, well below the profit level implied by recent quarters and trailing earnings. For a digital advertising and mobile marketing business priced for strong growth, that kind of profit squeeze is the...

Haitian International Holdings stock has been under pressure, down about 9% over the past week even before investors fully digested the latest half year report. The headline from these earnings is a margin squeeze that is starting to bite. Net profit margin over the last year slipped to 17.8% from 19.1%, and trailing earnings have softened after several years of slower growth. For short term traders that hurts. For long term investors the bigger question now is whether a roughly 8x P/E and...

China Resources Pharmaceutical Group stock closed at HK$4.65, capping a choppy few months in which the share price slipped over 5% in the past week and almost 1% over the past quarter. The market is still treating the company like a low-growth laggard with a P/E of about 6x, even as trailing net income from continuing operations reached ¥9.62b and net profit margin edged up to 1.5%. For anyone looking beyond today’s tick-by-tick moves, this earnings release is really a story about valuation...

In August 2026, United Company RUSAL International reported past half-year results to June 30, 2026, with sales rising to US$8,338 million from US$7,520 million and net income improving to US$419 million from a net loss of US$87 million a year earlier. This shift from loss to profit, alongside the Board’s approval of IFRS interim financial statements and review of budget execution, signals a clear turnaround in the company’s reported operational performance. We will now examine how the move...

TK Group (Holdings) closed at HK$1.61 today, with the stock under pressure over the past three months as investors reacted to weaker headline numbers. The market is clearly focused on the hit to profitability in the latest half. However, the real story sits in the widening gap between current margins and the growth and valuation profile that longer term forecasts imply. H1 2026 net income of HK$21.91 million and basic EPS of HK$0.026 underline that margin compression is the key issue. For...

TravelSky Technology walked into this earnings day with the stock roughly flat over the past quarter and modest gains over the last month, yet trading on a single digit P/E and a wide gap to analyst fair value estimates. The market now has to weigh that discount against one clear headline: Profitability in the core aviation software and services engine remains strong, with trailing net profit margin sitting at 27.1% and earnings over the last year higher than the prior year. The question is...

The market has barely flinched on Kerry Properties, with the stock edging only slightly higher into these H1 2026 results. Yet the earnings headline is far punchier than the share move suggests. Basic EPS came in at HK$0.51 and net income, excluding one off items, reached HK$735 million, which reinforces the recovery seen over the past year. For a Hong Kong developer that screens on a rich trailing P/E and carries a stretched dividend cover, this kind of earnings power is exactly what...

Kingboard Holdings stock has climbed 9.2% over the past month, yet the fresh H1 numbers land with a more complex message. Revenue reached HK$29,131.4m and basic earnings per share came in at HK$2.44, keeping the earnings recovery story alive. The real tension for sentiment sits in valuation. The stock trades on a 12.5x P/E, while a discounted cash flow estimate of HK$13.54 per share trails far behind the current HK$50.95 price. Today's reaction looks less like a simple earnings cheer and more...

Zhejiang Leapmotor Technology stock came into the earnings print with a mixed tape, down about 3% over the past week but still up around 11% over the past month. That backdrop matters because the headline from this report is clear. The company is now showing meaningful profit on fast growing electric vehicle volume, yet the shares still trade on a very rich trailing P/E of 68.9x. The sentiment test for you is simple. Are investors paying up for real earnings momentum or reacting emotionally...

Green Tea Group went into this earnings day with a stock that has drifted over the past quarter and now trades on a low P/E of 6.8x, despite analyst targets sitting far above the current HK$6.55 price. The headline from H1 2026 is simple: Revenue reached ¥2,691.4m and net income came in at ¥290.8m, which feeds into a trailing net margin of 10.6%. The gap between that profitability profile and the compressed valuation set the stage for today’s sharp debate over whether the market is mispricing...

InnoCare Pharma stock comes into this earnings story with a strong backdrop, up about 27% over the past three months and closing at HK$14.91 on 25 August. The headline today is simple: the market is reacting to a biopharma that has shifted from losses to profit while still leaning hard into research and development. The emotional tug of war sits between a clean profit print and what it took to get there. Second quarter revenue reached RMB 608.4m and basic earnings per share came in at RMB...

Sinopharm Group just delivered earnings that look stronger on paper than its recent share price would suggest. The stock closed at HK$15.95 and has drifted lower over the past week, month and quarter. Yet Q2 net income reached C¥1,989.8m with basic earnings per share of C¥0.64. For a distributor in China’s tightly regulated healthcare market, that profit line is the real headline. The key question for you now is how this earnings power lines up with a trailing P/E of about 6x and a business...

Q Technology (Group) went into this half-year update with a value label attached. The stock trades on a P/E of 4.2x and has slipped about 36% over the past three months, despite a trailing net margin of 6.7%. The headline this time is not revenue growth. It is the quality of those profits, with a large one off gain of CN¥875m running through the last twelve months. For investors, the real question now is how much of Q Technology’s earnings power is repeatable once that boost fades. Is Q...